AnaptysBio (ANAB) News Today $15.85 +0.82 (+5.46%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Leerink Partners Remains a Buy on AnaptysBio (ANAB)January 20 at 11:48 AM | markets.businessinsider.comAnaptys to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and eight have issued aJanuary 6, 2025 | marketbeat.comEcor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockJanuary 3, 2025 | insidertrades.comEcor1 Capital, Llc Purchases 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.January 2, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc Purchases 65,184 SharesAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc purchased 65,184 shares of the stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares of the company's stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 2, 2025 | marketbeat.comState Street Corp Sells 60,670 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)State Street Corp decreased its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 906,182 shares of the biotechnology compDecember 22, 2024 | marketbeat.comFranklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Franklin Resources Inc. decreased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 23.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 354,370 shares of the bioDecember 21, 2024 | marketbeat.comAnaptysBio price target lowered to $36 from $66 at JPMorganDecember 20, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. reduced their price target on AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a report on Thursday.December 19, 2024 | marketbeat.comAnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis ReadoutDecember 18, 2024 | seekingalpha.comDeep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)December 18, 2024 | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's What HappenedAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Still a Buy?December 18, 2024 | marketbeat.comTruist Financial Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $20.00Truist Financial lowered their price target on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a report on Wednesday.December 18, 2024 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)December 17, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Shares Up 9.1% - Here's What HappenedAnaptysBio (NASDAQ:ANAB) Shares Up 9.1% - Time to Buy?December 16, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short InterestAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 7,100,000 shares, an increase of 5.8% from the November 15th total of 6,710,000 shares. Based on an average daily trading volume, of 447,100 shares, the days-to-cover ratio is presently 15.9 days. Currently, 27.3% of the company's stock are short sold.December 16, 2024 | marketbeat.comAnaptysBio FY2024 EPS Estimate Increased by HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of AnaptysBio in a research report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($6.09)December 16, 2024 | marketbeat.comWhat is Wedbush's Estimate for AnaptysBio FY2024 Earnings?AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush reduced their FY2024 earnings per share (EPS) estimates for shares of AnaptysBio in a note issued to investors on Wednesday, December 11th. Wedbush analyst D. Nierengarten now expects that the biotechnology company willDecember 16, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for AnaptysBio Q1 Earnings?AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for AnaptysBio in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar forecasts that the biotechnology company will post earnings of ($1.44) per sharDecember 13, 2024 | marketbeat.comAnaptysBio price target lowered to $40 from $56 at Wells FargoDecember 13, 2024 | markets.businessinsider.comAnaptysBio price target lowered to $36 from $90 at GuggenheimDecember 13, 2024 | markets.businessinsider.comBuy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation OpportunityDecember 12, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades AnaptysBio (ANAB)December 12, 2024 | msn.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from AnalystsAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve analysts that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a bDecember 12, 2024 | marketbeat.comAnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares FallDecember 11, 2024 | marketwatch.comAnaptysBio (ANAB) Receives a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.comAnaptysBio to abandon eczema drug development after mid-stage trial failureDecember 11, 2024 | reuters.comAnaptysBio abandons eczema drug development after mid-stage trial failureDecember 11, 2024 | reuters.comAnaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisDecember 11, 2024 | globenewswire.comFrazier Life Sciences Management L.P. Purchases 43,598 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,209,189 shares of the biotechDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Increases Stake in AnaptysBio, Inc. (NASDAQ:ANAB)Point72 Asset Management L.P. raised its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 202.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,200 shares of the biotechnologDecember 10, 2024 | marketbeat.comVerition Fund Management LLC Acquires Shares of 22,036 AnaptysBio, Inc. (NASDAQ:ANAB)Verition Fund Management LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,036 shares of the biotechnologDecember 10, 2024 | marketbeat.comBNP Paribas Financial Markets Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB)BNP Paribas Financial Markets lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6,009.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,109 shares of the biotechnologyDecember 7, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Fmr LLCFmr LLC grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 15.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,309,175 shares of the biotechnology company's stockDecember 5, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 46.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 138,100 shares of the biotechnology company's stock after selling 11December 4, 2024 | marketbeat.comAnaptysBio downgraded to Neutral from Buy at BTIGDecember 3, 2024 | markets.businessinsider.comKey Takeaways From AnaptysBio Analyst RatingsDecember 3, 2024 | benzinga.comBTIG Downgrades AnaptysBio (ANAB)December 3, 2024 | msn.comAnaptysBio (NASDAQ:ANAB) Downgraded by BTIG Research to NeutralBTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday.December 2, 2024 | marketbeat.com163,997 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by Walleye Capital LLCWalleye Capital LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 163,997 shares of the biotechnology company's stock, valued at approximately $5,4December 2, 2024 | marketbeat.comCautious Optimism for AnaptysBio’s ANB032: Promising Preclinical Data Amid Efficacy UncertaintiesNovember 27, 2024 | markets.businessinsider.comJennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)Jennison Associates LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 264,889 shares of the biotechnology company's stock, valued at appNovember 23, 2024 | marketbeat.comVictory Capital Management Inc. Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)Victory Capital Management Inc. grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 677.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 237,250 shares ofNovember 22, 2024 | marketbeat.comAnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth WatchingNovember 21, 2024 | seekingalpha.comTruist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)November 20, 2024 | markets.businessinsider.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy ratiNovember 17, 2024 | marketbeat.comBroker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging HigherNovember 16, 2024 | finance.yahoo.comTD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)November 15, 2024 | markets.businessinsider.comAnaptysBio price target lowered to $66 from $75 at JPMorganNovember 12, 2024 | markets.businessinsider.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.500.44▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼14▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Today Agios Pharmaceuticals News Today Iovance Biotherapeutics News Today Tarsus Pharmaceuticals News Today Akero Therapeutics News Today Belite Bio News Today Disc Medicine News Today Amphastar Pharmaceuticals News Today Wave Life Sciences News Today Apogee Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts